Cargando…
The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients
Gut microbiota plays an essential role in the development of rheumatoid arthritis (RA) and affects drug responses. However, the underlying mechanism remains elusive and urgent to elucidate to explore the pathology and clinical treatment of RA. Therefore, we selected methotrexate (MTX) as an example...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024311/ https://www.ncbi.nlm.nih.gov/pubmed/35464950 http://dx.doi.org/10.3389/fmicb.2022.839015 |
_version_ | 1784690550781247488 |
---|---|
author | Han, Maozhen Zhang, Na Mao, Yujie Huang, Bingbing Ren, Mengfei Peng, Zhangjie Bai, Zipeng Chen, Long Liu, Yan Wang, Shanshan Huang, Shenghai Cheng, Zhixiang |
author_facet | Han, Maozhen Zhang, Na Mao, Yujie Huang, Bingbing Ren, Mengfei Peng, Zhangjie Bai, Zipeng Chen, Long Liu, Yan Wang, Shanshan Huang, Shenghai Cheng, Zhixiang |
author_sort | Han, Maozhen |
collection | PubMed |
description | Gut microbiota plays an essential role in the development of rheumatoid arthritis (RA) and affects drug responses. However, the underlying mechanism remains elusive and urgent to elucidate to explore the pathology and clinical treatment of RA. Therefore, we selected methotrexate (MTX) as an example of RA drugs to explore the interactions between the gut microbiota and drug responses and obtain an in-depth understanding of their correlation from the perspective of the metabolic capability of gut microbiota on drug metabolism. We identified 2,654 proteins and the corresponding genes involved in MTX metabolism and then profiled their abundances in the gut microbiome datasets of four cohorts. We found that the gut microbiota harbored various genes involved in MTX metabolism in healthy individuals and RA patients. Interestingly, the number of genes involved in MTX metabolism was not significantly different between response (R) and non-response (NR) groups to MTX, but the gene composition in the microbial communities significantly differed between these two groups. Particularly, several models were built based on clinical information, as well as data on the gene, taxonomical, and functional biomarkers by using the random forest algorithm and then validated. Our findings provide bases for clinical management not only of RA but also other gut microbiome–related diseases. First, it suggests that the potential metabolic capability of gut microbiota on drug metabolism is important because they affect drug efficiency; as such, clinical treatment strategies should incorporate the gene compositions of gut microbial communities, in particular genes involved in drug metabolism. Second, a suitable model can be developed to determine hosts’ responses to drugs before clinical treatment. |
format | Online Article Text |
id | pubmed-9024311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90243112022-04-23 The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients Han, Maozhen Zhang, Na Mao, Yujie Huang, Bingbing Ren, Mengfei Peng, Zhangjie Bai, Zipeng Chen, Long Liu, Yan Wang, Shanshan Huang, Shenghai Cheng, Zhixiang Front Microbiol Microbiology Gut microbiota plays an essential role in the development of rheumatoid arthritis (RA) and affects drug responses. However, the underlying mechanism remains elusive and urgent to elucidate to explore the pathology and clinical treatment of RA. Therefore, we selected methotrexate (MTX) as an example of RA drugs to explore the interactions between the gut microbiota and drug responses and obtain an in-depth understanding of their correlation from the perspective of the metabolic capability of gut microbiota on drug metabolism. We identified 2,654 proteins and the corresponding genes involved in MTX metabolism and then profiled their abundances in the gut microbiome datasets of four cohorts. We found that the gut microbiota harbored various genes involved in MTX metabolism in healthy individuals and RA patients. Interestingly, the number of genes involved in MTX metabolism was not significantly different between response (R) and non-response (NR) groups to MTX, but the gene composition in the microbial communities significantly differed between these two groups. Particularly, several models were built based on clinical information, as well as data on the gene, taxonomical, and functional biomarkers by using the random forest algorithm and then validated. Our findings provide bases for clinical management not only of RA but also other gut microbiome–related diseases. First, it suggests that the potential metabolic capability of gut microbiota on drug metabolism is important because they affect drug efficiency; as such, clinical treatment strategies should incorporate the gene compositions of gut microbial communities, in particular genes involved in drug metabolism. Second, a suitable model can be developed to determine hosts’ responses to drugs before clinical treatment. Frontiers Media S.A. 2022-04-08 /pmc/articles/PMC9024311/ /pubmed/35464950 http://dx.doi.org/10.3389/fmicb.2022.839015 Text en Copyright © 2022 Han, Zhang, Mao, Huang, Ren, Peng, Bai, Chen, Liu, Wang, Huang and Cheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Han, Maozhen Zhang, Na Mao, Yujie Huang, Bingbing Ren, Mengfei Peng, Zhangjie Bai, Zipeng Chen, Long Liu, Yan Wang, Shanshan Huang, Shenghai Cheng, Zhixiang The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients |
title | The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients |
title_full | The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients |
title_fullStr | The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients |
title_full_unstemmed | The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients |
title_short | The Potential of Gut Microbiota Metabolic Capability to Detect Drug Response in Rheumatoid Arthritis Patients |
title_sort | potential of gut microbiota metabolic capability to detect drug response in rheumatoid arthritis patients |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024311/ https://www.ncbi.nlm.nih.gov/pubmed/35464950 http://dx.doi.org/10.3389/fmicb.2022.839015 |
work_keys_str_mv | AT hanmaozhen thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT zhangna thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT maoyujie thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT huangbingbing thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT renmengfei thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT pengzhangjie thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT baizipeng thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT chenlong thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT liuyan thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT wangshanshan thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT huangshenghai thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT chengzhixiang thepotentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT hanmaozhen potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT zhangna potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT maoyujie potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT huangbingbing potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT renmengfei potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT pengzhangjie potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT baizipeng potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT chenlong potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT liuyan potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT wangshanshan potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT huangshenghai potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients AT chengzhixiang potentialofgutmicrobiotametaboliccapabilitytodetectdrugresponseinrheumatoidarthritispatients |